

Research Article

Zearalenone Inhibits Rat and Human 11 β -Hydroxysteroid Dehydrogenase Type 2

Linxi Li,¹ Xiaolong Wu,¹ Hongguo Guan,¹ Baiping Mao,² Huang Wang,¹ Xiaohuan Yuan,³ Yanhui Chu,³ Jianliang Sun,⁴ and Ren-Shan Ge²

¹Center of Scientific Research, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China

²Department of Anesthesiology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China

³Heilongjiang Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Heilongjiang 157011, China
⁴Department of Anesthesia, Hangzhou Hospital Affiliated to Nanjing Medical University, Hangzhou First People's Hospital, Hangzhou 310006, China

Correspondence should be addressed to Jianliang Sun; jxmzsjl@163.com and Ren-Shan Ge; r_ge@yahoo.com

Received 6 October 2015; Accepted 1 December 2015

Academic Editor: Koichiro Wada

Copyright © 2015 Linxi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zearalenone is a mycotoxin produced by *Fusarium* spp. 11 β -Hydroxysteroid dehydrogenases, isoforms 1 (HSD11B1) and 2 (HSD11B2), have been demonstrated to be the regulators of the local level of active glucocorticoid, which has a broad range of physiological actions. In the present study, the potency of zearalenone was tested for the inhibition of HSD11B1 and HSD11B2 in rat and human tissues. Zearalenone showed potent inhibition of HSD11B2 with the half-maximal inhibitory concentration (IC₅₀) calculated at 49.63 and 32.22 μ M for the rat and human, respectively. Results showed that zearalenone competitively inhibited HSD11B2 when a steroid substrate was used. However, it served as an uncompetitive inhibitory factor when the cofactor NAD⁺ was used. In contrast, the potency of zearalenone to inhibit both rat and human HSD11B1 was diminished, with the concentration of 100 μ M causing almost no inhibitory effect on the isoform. In conclusion, we observed that zearalenone is a selective inhibitor of HSD11B2, implying that this agent may cause excessive glucocorticoid action in local tissues such as kidney and placentas.

1. Introduction

Zearalenone is a mycotoxin produced by *Fusarium* spp. [1]. Although zearalenone is structurally dissimilar to estradiol, it possesses estrogenic activity. The molecule of zearalenone undergoes folding such that the molecule can bind to an estrogen receptor [1]. Zearalenone is found in a number of cereal crops, such as wheat, maize, barley, oats, rice, and sorghum [2]. It is very stable in foods even during heat processing. Therefore, it can be ingested into human bodies without damage of its active molecule.

Zearalenone mainly targets reproductive system [3], because it has weak estrogen activity. Apparently, it has about 20-fold lower binding to estrogen receptor than the endogenous estrogen estradiol [1]. However, zearalenone has also been shown to exert toxicity to immune system, liver, and lipid peroxidation [4].

Glucocorticoids play a wide range of physiological and pharmacological roles in mammalian physiology [5, 6]. Glucocorticoid exerts its actions after binding to its nuclear receptor, glucocorticoid receptor, thus regulating gene expression in target tissues and thereby causing their action. Intracellular levels of glucocorticoids (cortisol in humans and corticosterone in rats) are controlled by the glucocorticoid metabolizing enzyme 11 β -hydroxysteroid dehydrogenase (HSD11B). There are two known isoforms. Type I isoform, HSD11B1, is NADP⁺/NADPH dependent oxidoreductase that catalyzes the interconversion of 11 β -hydroxyl steroids and 11-keto steroids, for example, cortisone in



FIGURE 1: The illustration of catalytic reactions of 11β -hydroxysteroid dehydrogenase isoforms (HSD11B1 and HSD11B2) (a) and the chemical structure of phenol red and zearalenone (b).

humans and 11-dehydrocorticosterone (11DHC) in rats. The HSD11B1 isoform is most abundantly expressed in glucocorticoid target tissues such as liver, fat, brain, and testis [7] (Figure 1). HSD11B1 has low-affinity binding to its steroid substrate with K_m of approximately $2 \mu M$ [8]. HSD11B1 behaves predominantly as a reductase in liver and fat, thus regenerating active 11β -hydroxyl glucocorticoids from the circulatory inactive 11-keto glucocorticoids [7]. Interestingly, increased HSD11B1 activity in the liver and adipose tissue has been thought to contribute to the etiology of metabolic syndromes [7].

The second isoform, HSD11B2, is a unidirectional NAD⁺ dependent oxidase, which inactivates 11β -hydroxyl glucocorticoids (Figure 1), thereby preventing binding of the mineralocorticoid receptor by natural glucocorticoids [9]. Genetically null mutations of the HSD11B2 gene in the human cause a syndrome named apparent mineralocorticoid excess in which circulatory aldosterone levels are subnormal and are related to hypertension and hypokalemia [10]. Furthermore, HSD11B2 is thought to be a critical gatekeeper that eliminates active glucocorticoids in the maternal side of the placenta in order to protect the fetus from unusually high glucocorticoid concentrations [11]. Indeed, a previous report demonstrated that mutation and inhibition of HSD11B2 that was occasioned by exposure to chemicals caused placental dysfunction associated with low birth weight [12]. By virtual screening, we have observed that zearalenone is a possible inhibitor of the HSD11B enzyme. In the present study, we performed experiments to determine the direct suppression of both HSD11B isoform and the possible mechanism of zearalenone. Our findings suggest that zearalenone is primarily a selective inhibitor of HSD11B2 in rat and human tissues.

2. Materials and Methods

2.1. Chemicals and Animals. [1,2-³H]-Corticosterone (³Hcorticosterone) (specific activity: 40 Ci/mmol) and [1,2,6,7-³H(N)]-cortisol (specific activity: 70–100 Ci/mmol) were purchased from DuPont-New England Nuclear (Boston, MA). [1,2-³H]-11-Dehydrocorticosterone (³H-11DHC) and [1,2,6,7-³H(N)]-cortisone were prepared from labeled ³Hcorticosterone or ³H-cortisol as described earlier [13]. Unlabeled corticosterone, 11DHC, cortisol, and cortisone were purchased from Steraloids (Wilton, NH). Zearalenone was purchased from Sigma (St. Louis, MO). Male Sprague-Dawley rats (250-300 g) were purchased from Shanghai Laboratory Animal Center (Shanghai, China). The experimental protocol was approved by the Wenzhou Medical University's Animal Care and Use Committee. Human liver microsomes were purchased from BD Gentest (NJ, USA). Full-term human placentas were obtained from the 2nd Affiliated Hospital of Wenzhou Medical University under the approval of the Ethics Committee of the hospital.

2.2. Preparation of Microsomal Protein. Microsomal preparations of rat liver and kidney and human placentas were prepared as described previously [14]. Briefly, samples were homogenized in cold 0.01 M phosphate buffered saline (PBS) containing 0.25 M sucrose and centrifuged at $700 \times g$ for

30 min. The supernatants were transferred to new tubes and centrifuged at $10,000 \times g$ for 30 min. The supernatants were centrifuged twice at $105,000 \times g$ for 1 hour (twice). Pellets were resuspended and protein contents were measured. The protein concentrations were measured using the Bio-Rad Protein Assay Kit (cat.# 500-0006, Bio-Rad, Hercules, CA) according to the manufacturer's protocol. Microsomes from all tissues were used for measurement of HSD11B activities.

2.3. HSD11B Assay. HSD11B1 activity was measured in rat and human liver microsomes using $[^{3}H]$ -11DHC or $[^{3}H]$ -cortisone, respectively, according to a previously described method [14]. The assay tubes contained 200 nM cortisone or 11DHC and 0.2 mM NADPH and 2 mM glucose-6-phosphate. The microsomes were preincubated with zear-alenone for 2 min and then added to the above tubes. The initial test concentration for zearalenone was 100 μ M.

HSD11B2 activity was measured in rat kidney and human placental microsomes using [³H]-corticosterone or [³H]-cortisol, respectively, according to a previously described method [14]. The assay tubes contained 25 nM corticosterone or cortisol and 0.2 mM NAD⁺ and 2 mM DTT. The microsomes were preincubated with zearalenone for 2 min and then added to the above tubes. The initial test concentration for zearalenone was 100 μ M. When the inhibitory concentration was established, different concentrations of zearalenone were used.

On each occasion, the reactions were stopped by adding 2 mL ice-cold ether. The steroids were extracted, and the organic layer was dried under nitrogen. The steroids were separated chromatographically on thin layer plates in chloroform and methanol (90:10, v/v), and the radioactivity was measured using a scanning radiometer (System AR2000, Bioscan Inc., Washington, DC). HSD11B1 activity was determined by the percentage conversion of 11DHC to corticosterone or cortisone to cortisol and HSD11B2 activity by the conversion of corticosterone to 11DHC or cortisol to cortisone by dividing the radioactive counts identified by the total counts associated with substrate and products.

2.4. Analysis of Enzyme Kinetics. The dose-dependent inhibition of zearalenone on HSD11B was subjected to nonlinear analysis by GraphPad (Version 6, GraphPad Software Inc., San Diego, CA), and half-maximal inhibitory concentrations (IC_{50}) were calculated. Michaelis-Menten kinetics and Lineweaver-Burk plots were drawn for the analysis of the mode of inhibition of zearalenone.

2.5. Statistics. Each experiment was repeated four to six times. Data were subjected to analysis by unpaired Student *t*-tests to identify significant differences between two groups. All data are expressed as means SEM. Differences were regarded as significant at P < 0.05.

3. Results

3.1. Effects of Zearalenone on HSD11B1 Activity. Because HSD11B1 is an oxidoreductase, reductase activity was

measured in the presence of the cofactor NADPH. We also compared the zearalenone with another weak estrogen phenol red, which has also hydroxyl group in its chemical structure. At 100 μ M, zearalenone showed weak but significant inhibition of the rat HSD11B1 reductase (Figure 2(a)), while phenol red did not affect rat HSD11B1 activity (Figure 3(b)). Both zearalenone and phenol red weakly inhibited human HSD11B1 activity (Figure 2(b)). However, the inhibition of HSD11B1 by 100 μ M zearalenone never exceeded 50%. Together, results indicate that both phenol red and zearalenone have almost no inhibitory effect on both rat and human HSD11B1 at 100 μ M or below.

3.2. Effects of Zearalenone on HSD11B2 Activity. HSD11B2 is a unidirectional oxidase, and its activity was measured in the presence of the cofactor NAD⁺. Zearalenone exhibited potent and significant inhibition (>50%) of rat and human HSD11B2 activity at the 100 μ M concentration (Figures 3(a) and 3(b)). Phenol red had no inhibition on rat HSD11B2 activity, but it inhibited human HSD11B2 activity (Figure 3). In addition, analysis of dose-dependent zearalenone inhibition of HSD11B2 activity estimated IC₅₀ values of 49.63 ± 0.07 and 32.22 ± 0.09 μ M for rat and human HSD11B2 activities, respectively (Figure 4). The results imply that zearalenone has a potent to moderate capacity to cause inhibition of both rat and human HSD11B2.

3.3. The Mode of Inhibition of Zearalenone on HSD11B2 Activity. The HSD11B2 enzyme has dual substrates, that is, steroid and cofactor (NAD⁺). At first, we tested the mode of inhibition of zearalenone on this enzyme when cortisol was used for human enzyme. Michaelis-Menten kinetics (Figure 5(a)) and Lineweaver-Burk plots (Figure 5(b)) showed that zearalenone was a competitive inhibitor for human HSD11B2. This was true for rat HSD11B2 when corticosterone was used (data not shown). This indicates that zearalenone competes with the steroid substrate at its binding site. When the cofactor NAD^+ was used, Michaelis-Menten kinetics (Figure 6(a)) and Lineweaver-Burk plots (Figure 6(b)) showed that zearalenone was an uncompetitive inhibitor for human HSD11B2. This was also true for rat HSD11B2 when corticosterone was used (data not shown). These results indicate that zearalenone binds to HSD11B2-NAD⁺-corticosterone complex.

4. Discussion

The widespread availability of zearalenone from the food resources has given rise to public concerns about its adverse effects on the population. Although many studies have investigated the pharmacological activities of zearalenone in several animal models for its toxicity in reproductive system, the mechanisms of action of zearalenone are not fully understood. The present study showed that zearalenone inhibited the HSD11B2 enzyme in rat and human tissues with IC₅₀ values in the range 32–49 μ M. It virtually has almost no inhibitory effect on HSD11B1 isoform. This finding indicates that zearalenone is a more specific inhibitor of the HSD11B2 enzyme.



FIGURE 2: The effects of zearalenone (ZEN) and phenol red (PR) on rat (a) and human 11 β -hydroxysteroid dehydrogenase isoform 1 (HSD11B1) (b) were tested at the 100 μ M concentration. Graph includes results from four to six separate and independent experiments. Mean ± SEM; ** and * * * indicate significant difference compared to control at *P* < 0.01 and 0.001, respectively.



FIGURE 3: The effects of zearalenone (ZEN) and phenol red (PR) on rat (a) and human 11 β -hydroxysteroid dehydrogenase isoform 2 (HSD11B2) (b) were tested at the 100 μ M concentration. Graph includes results from four to six separate and independent experiments. Mean ± SEM; * * * indicates significant difference compared to control at *P* < 0.001.



FIGURE 4: Dose-dependent inhibition of rat (a) and human 11β -hydroxysteroid dehydrogenase isoform 2 (HSD11B2) by zearalenone (ZEN) (b). Mean \pm SEM; graph includes results from four separate and independent experiments.



FIGURE 5: The mode of action of zearalenone (ZEN) on human 11β -hydroxysteroid dehydrogenase isoform 2 (HSD11B2). The HSD11B2 activity was analyzed using different concentrations of cortisol. (a) Michaelis-Menten kinetics; (b) Lineweaver-Burk plots. Graph includes results from four separate and independent experiments.



FIGURE 6: The mode of action of butylated hydroxyanisole (ZEN) on human 11 β -hydroxysteroid dehydrogenase isoform 2 (HSD11B2). The HSD11B2 activity was investigated using different concentrations of cofactor NAD⁺. (a) Michaelis-Menten kinetics; (b) Lineweaver-Burk plots. Graph includes results from four separate and independent experiments.

In the placentae, HSD11B2 protects the fetus from the high circulating levels of maternal glucocorticoids [11, 15, 16] by helping in elimination of maternal cortisol [17, 18]. Mouse models with null mutation of *Hsd11b2* gene showed placental anomalies and dysfunction that resulted in intrauterine fetal growth retardation [12]. Thus, our observations imply that zearalenone-related inhibition of HSD11B2 during pregnancy is associated with glucocorticoid-mediated effects that potentially cause adverse consequences on fetal development.

Moreover, HSD11B2 is thought to be the gatekeeper for mineralocorticoid receptors in its target tissue such as kidney

and colon [10]. Usually, mineralocorticoid receptors have no selectivity for aldosterone (a natural mineralocorticoid) or cortisol (a natural glucocorticoid) with serum concentrations that are 100-fold greater than aldosterone [19]. Thus, the high affinity of HSD11B2 for cortisol effectively inactivates this compound through its metabolic conversion to cortisone, which has negligible binding affinity to the mineralocorticoid receptor [20, 21]. Indeed, null mutation of the *HSD11B2* [22] or pharmacological inhibition by chemicals has shown that mineralocorticoid receptors in the kidney are occupied by cortisol, causing apparent mineralocorticoid excess

associated in part with hypertension and hypokalemia [23, 24]. It does appear that the HSD11B2 isoform is essential for maintaining physiological levels of aldosterone activity.

There is evidence that zearalenone may interfere with development of the testis and male reproductive tract. Mice administered orally with a single dose (zearalenone) had reduced testosterone level [25]. Adult male mice were administered intraperitoneally with zearalenone at 0, 25, 50, and 75 mg/kg body weight daily for 7 days, and zearalenone significantly reduced serum testosterone level [26]. HSD11B2 has been shown to be present in fetal and adult mammalian (human, rat, and pig) Leydig cells [27–29]. Therefore, HSD11B2 may play an important role in glucocorticoid inactivation in Leydig cells to prevent glucocorticoid-mediated suppression of testosterone directly binds to the glucocorticoid receptor in Leydig cells and inhibits androgen biosynthesis [29–31].

Overall, zearalenone has greater selectivity for HSD11B2 versus the HSD11B1 enzyme, because it inhibited rat and human HSD11B2 with IC₅₀ values of 32–49 μ M, while it almost lacked effective inhibition of rat and human HSD11B1 even at 100 μ M. Structurally, zearalenone is a phenol with a hydroxyl group, which is similar to 11-beta hydroxyl group in cortisol and cortisone. The action of zearalenone on HSD11B2 appears to be similar to that reported for another polyphenolic compound, that is, gossypol, which is also highly selective for HSD11B2 compared to HSD11B1 [14]. However, HSD11B2 is a dual substrate enzyme, which needs the cofactor NAD⁺. When NAD⁺ was used, zearalenone showed mixed uncompetitive inhibition, indicating that zearalenone binds to NAD⁺-bounded enzyme complex.

5. Conclusions

We tested the effects of zearalenone on HSD11B1 and HSD11B2 and found that zearalenone selectively inhibited both rat and human HSD11B2 enzyme. The mode of action of zearalenone on HSD11B2 is a competition when a gluco-corticoid substrate is used.

Abbreviations

11DHC:	11-Dehydrocorticosterone
HSD11B:	11β -Hydroxysteroid dehydrogenase
HSD11B1:	11 β -Hydroxysteroid dehydrogenase 1
HSD11B2:	11 β -Hydroxysteroid dehydrogenase 2
IC ₅₀ :	Half-maximal inhibitory concentrations
PBS:	Phosphate buffered saline
PR:	Phenol red
ZEN:	Zearalenone.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Linxi Li and Xiaolong Wu contributed equally to this work.

Acknowledgments

This work was partially supported by the Health Bureau of Zhejiang Province (WKJ2011-2-012, 11-CX29, 2013ZDA017, 2014KYA263, and 2014C37017) and Wenzhou Science & Technology Bureau (Y20140657).

References

- M. A. Diekman and M. L. Green, "Mycotoxins and reproduction in domestic livestock," *Journal of Animal Science*, vol. 70, no. 5, pp. 1615–1627, 1992.
- [2] T. Kuiper-Goodman, P. M. Scott, and H. Watanabe, "Risk assessment of the mycotoxin zearalenone," *Regulatory Toxicology and Pharmacology*, vol. 7, no. 3, pp. 253–306, 1987.
- [3] F. Minervini and M. E. D. Aquila, "Zearalenone and reproductive function in farm animals," *International Journal of Molecular Sciences*, vol. 9, no. 12, pp. 2570–2584, 2008.
- [4] D. E. Marin, I. Taranu, R. Burlacu et al., "Effects of zearalenone and its derivatives on porcine immune response," *Toxicology in Vitro*, vol. 25, no. 8, pp. 1981–1988, 2011.
- [5] R. H. Oakley and J. A. Cidlowski, "Glucocorticoid signaling in the heart: a cardiomyocyte perspective," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 153, pp. 27–34, 2015.
- [6] H. Palma-Gudiel, A. Córdova-Palomera, J. C. Leza, and L. Fañanás, "Glucocorticoid receptor gene (NR3C1) methylation processes as mediators of early adversity in stress-related disorders causality: a critical review," *Neuroscience & Biobehavioral Reviews*, vol. 55, pp. 520–535, 2015.
- [7] J. W. Tomlinson, E. A. Walker, I. J. Bujalska et al., "11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response," *Endocrine Reviews*, vol. 25, no. 5, pp. 831–866, 2004.
- [8] V. Lakshmi and C. Monder, "Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex," *Endocrinol*ogy, vol. 123, no. 5, pp. 2390–2398, 1988.
- [9] A. S. Alzahrani, N. Aljuhani, E. Qasem et al., "Apparent mineralocorticoid excess caused by a novel mutation in $11-\beta$ hydroxysteroid dehydrogenase type 2 enzyme: its genetics and response to therapy," *Endocrine Practice*, vol. 20, no. 9, pp. el51–el56, 2014.
- [10] P. C. White, T. Mune, F. M. Rogerson, K. M. Kayes, and A. K. Agarwal, "11β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess," *Pediatric Research*, vol. 41, no. 1, pp. 25–29, 1997.
- [11] E. Kajantie, L. Dunkel, U. Turpeinen et al., "Placental 11βhydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants," *Journal of Clinical Endocrinol*ogy and Metabolism, vol. 88, no. 1, pp. 493–500, 2003.
- [12] X. Ma, Q.-Q. Lian, Q. Dong, and R.-S. Ge, "Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2," *Toxicology*, vol. 285, no. 3, pp. 83–89, 2011.
- [13] V. Lakshmi and C. Monder, "Extraction of 11β-hydroxysteroid dehydrogenase from rat liver microsomes by detergents," *Journal of Steroid Biochemistry*, vol. 22, no. 3, pp. 331–340, 1985.

- [14] B. B. Chen, H. Lin, G. X. Hu et al., "The (+)- and (-)gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 113, no. 3–5, pp. 177–181, 2009.
- [15] J. R. Seckl and M. C. Holmes, "Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology," *Nature Clinical Practice Endocrinology* and Metabolism, vol. 3, no. 6, pp. 479–488, 2007.
- [16] R. Benediktsson, A. A. Calder, C. R. W. Edwards, and J. R. Seckl, "Placental 11β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure," *Clinical Endocrinology*, vol. 46, no. 2, pp. 161–166, 1997.
- [17] J. R. Seckl, R. Benediktsson, R. S. Lindsay, and R. W. Brown, "Placental 11β-hydroxysteroid dehydrogenase and the programming of hypertension," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 55, no. 5-6, pp. 447–455, 1995.
- [18] M. Hill, A. Pašková, R. Kančeva et al., "Steroid profiling in pregnancy: a focus on the human fetus," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 139, pp. 201–222, 2014.
- [19] J. L. Arriza, C. Weinberger, G. Cerelli et al., "Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor," *Science*, vol. 237, no. 4812, pp. 268–275, 1987.
- [20] A. K. Agarwal, T. Mune, C. Monder, and P. C. White, "Cloning of cDNA encoding an NAD⁺-dependent isoform of 11βhydroxysteroid dehydrogenase in sheep kidney," *Endocrine Research*, vol. 21, no. 1-2, pp. 389–397, 1995.
- [21] Z. Krozowski, J. A. Maguire, A. N. Stein-Oakley, J. Dowling, R. E. Smith, and R. K. Andrews, "Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta," *Journal of Clinical Endocrinology and Metabolism*, vol. 80, no. 7, pp. 2203–2209, 1995.
- [22] T. Mune, F. M. Rogerson, H. Nikkilä, A. K. Agarwal, and P. C. White, "Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase," *Nature Genetics*, vol. 10, no. 4, pp. 394–399, 1995.
- [23] C. R. W. Edwards, D. Burt, M. A. Mcintyre et al., "Localisation of 11β-hydroxysteroid dehydrogenase—tissue specific protector of the mineralocorticoid receptor," *The Lancet*, vol. 332, no. 8618, pp. 986–989, 1988.
- [24] J. W. Funder, P. T. Pearce, R. Smith, and A. I. Smith, "Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated," *Science*, vol. 242, no. 4878, pp. 583–585, 1988.
- [25] S. P. Boeira, V. R. Funck, C. Borges Filho et al., "Lycopene protects against acute zearalenone-induced oxidative, endocrine, inflammatory and reproductive damages in male mice," *Chemico-Biological Interactions*, vol. 230, pp. 50–57, 2015.
- [26] J. Y. Yang, G. X. Wang, J. L. Liu, J. J. Fan, and S. Cui, "Toxic effects of zearalenone and its derivatives α-zearalenol on male reproductive system in mice," *Reproductive Toxicology*, vol. 24, no. 3-4, pp. 381–387, 2007.
- [27] Y. Honda, S. Ohno, and S. Nakajin, "Leydig cells from neonatal pig testis abundantly express 11β-hydroxysteroid dehydrogenase (11β-HSD) type 2 and effectively inactivate cortisol to cortisone," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 108, no. 1-2, pp. 91–101, 2008.
- [28] A. L. Albiston, V. R. Obeyesekere, R. E. Smith, and Z. S. Krozowski, "Cloning and tissue distribution of the human 1 lβhydroxysteroid dehydrogenase type 2 enzyme," *Molecular and Cellular Endocrinology*, vol. 105, no. 2, pp. R11–R17, 1994.
- [29] R.-S. Ge, Q. Dong, E.-M. Niu et al., "11β-hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid

action at physiological levels of substrate," *Endocrinology*, vol. 146, no. 6, pp. 2657–2664, 2005.

- [30] D. B. Hales and A. H. Payne, "Glucocorticoid-mediated repression of P450_{SCC} mRNA and de novo synthesis in cultured Leydig cells," *Endocrinology*, vol. 124, no. 5, pp. 2099–2104, 1989.
- [31] M. P. Hardy, C. M. Sottas, R. Ge et al., "Trends of reproductive hormones in male rats during psychosocial stress: role of glucocorticoid metabolism in behavioral dominance," *Biology* of *Reproduction*, vol. 67, no. 6, pp. 1750–1755, 2002.









Autoimmune Diseases











Anesthesiology Research and Practice





Emergency Medicine International



BioMed Research International



Pain Research and Treatment



International Journal of Medicinal Chemistry





Journal of Vaccines



